Interchangeable biosimilar sponsors may gain the ability to share the associated exclusivity, similar to what often occurs among small-molecule generics.
A bill in development would ensure all sponsors who are the “first filers” for interchangeable status can receive the one...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?